Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Tyra Biosciences, Inc.

Ticker
TYRA
Sector
Industry
Report date
November 10, 2026
Valye AI Score

73

High visibility
Recent developments
Recent developments summary

Recent developments for Tyra Biosciences include positive clinical trial results, a significant equity offering to fund development, and active analyst coverage with varied recommendations.

Recent developments:
  • Tyra Biosciences reported positive SURF302 clinical trial results and announced plans for a Phase 3 trial in low-grade intermediate-risk non-muscle invasive bladder cancer as of September 2026 [N5].
  • The company completed a $400 million underwritten offering of stock and warrants to advance its Dabogratinib 3x3 clinical program in September 2026 [N3].
  • Tyra Biosciences was highlighted among biotech stocks making gains in September 2026, reflecting market interest [N2].
  • Analyst coverage includes Wolfe Research initiating coverage with a peer perform recommendation in May 2026 [N7].
  • The company’s stock experienced a 27% decline over four weeks but was noted as poised for a turnaround in October 2026 [N1].
Overview

Tyra Biosciences, Inc. operates in the biotechnology sector focusing on clinical-stage drug development. The company is advancing its Dabogratinib 3x3 program and SURF302 candidate, targeting oncology indications such as non-muscle invasive bladder cancer. Tyra Biosciences has recently reported positive clinical data and is preparing for pivotal Phase 3 trials. The company has raised capital through a significant underwritten stock and warrant offering to fund its clinical pipeline. Financial disclosures indicate a strong cash position and liquidity, supporting ongoing operations and development activities.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Tyra Biosciences, Inc. is a biotechnology company engaged in clinical development of therapies, notably advancing Dabogratinib and SURF302 programs. The company reported positive clinical trial results and plans for Phase 3 studies. It completed a $400 million equity offering to support development. As of September 30, 2026, Tyra Biosciences held $456 million in cash and equivalents with strong liquidity ratios and reported a net loss of $51.1 million for the quarter. The company has received varied analyst coverage and experienced notable stock price volatility in recent periods.

Scenarios for TYRA

Bull case model:

Tyra Biosciences has demonstrated clinical progress with positive SURF302 results and plans for Phase 3 trials, supported by a substantial capital raise. Analyst coverage and investor interest have been strong, reflecting confidence in the company’s pipeline potential. The company’s strong liquidity position provides financial flexibility to advance its programs.

Bear case model:

Risks include the inherent uncertainties of clinical development, potential regulatory hurdles, and the need for continued financing beyond current cash reserves. Recent stock price volatility and losses highlight market sensitivity to clinical and operational developments. The company’s success depends on execution of clinical milestones and regulatory approvals.

Moat:

Tyra Biosciences’ moat is primarily based on its clinical-stage drug candidates and proprietary development programs in oncology. The company’s ability to advance clinical trials and secure financing contributes to its competitive positioning. However, as a clinical-stage biotech, it faces typical industry risks including regulatory approval challenges, clinical trial outcomes, and competition from other drug developers.

Risks overview
Risks summary
The primary risk for Tyra Biosciences is the uncertainty inherent in clinical development and regulatory approval processes, which directly impact its ability to commercialize drug candidates and achieve financial sustainability.
Risks details:

• Clinical Development Risk: The success of Tyra Biosciences depends on positive outcomes from ongoing and planned clinical trials, which are inherently uncertain.
• Regulatory Risk: Obtaining regulatory approvals for drug candidates involves complex processes with no guarantee of success.
• Financial Risk: Despite strong liquidity as of September 2026, the company may require additional financing to support long-term development and commercialization.
• Market Volatility: The company’s stock has experienced significant price fluctuations, reflecting sensitivity to clinical and market developments.

FINAL FORECAST FOR TYRA

Final take one line
Tyra Biosciences exhibits very high visibility supported by detailed clinical progress, strong liquidity, and active market and analyst engagement.
Final take 12 to 24 month view

Business trends: Clinical advancement of Dabogratinib and SURF302 programs with planned Phase 3 trials and capital raising activities.
Execution milestones: Completion of $400 million equity offering, positive clinical trial results, and initiation of pivotal Phase 3 studies.
Key risks: Clinical and regulatory uncertainties, need for ongoing financing, and stock price volatility reflecting market sensitivity.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

73
LLM visibility overview
LLM Visibility known facts
  • Tyra Biosciences, Inc. is a biotechnology company with active clinical development programs.
  • The company reported positive SURF302 clinical trial results and plans to initiate a Phase 3 trial in low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC) as of September 2026 [N5].
  • Tyra Biosciences completed a $400 million underwritten offering of stock and warrants to advance its Dabogratinib 3x3 clinical program in September 2026 [N3].
  • The company’s latest SEC 10-Q filing as of September 30, 2026, reports cash and cash equivalents of $456.0 million, current assets of $711.6 million, and current liabilities of $29.7 million, resulting in a current ratio of 23.93 and a cash ratio of 15.33, indicating strong liquidity [S2].
  • Net income for the quarter ending September 30, 2026, was a loss of $51.1 million, with basic and diluted EPS of -$0.74 per share [S2].
  • Tyra Biosciences has received analyst coverage with recommendations ranging from peer perform to buy and overweight from various firms in 2026 [N7, N8].
  • The company’s stock has experienced significant price movements, including a 280% increase over one year and a recent 27% decline over four weeks, with commentary on potential turnaround [N1, N8].
  • Recent news highlights active option activity and gains in biotech stocks including Tyra Biosciences [N2, N6].
Sources
Sources - Context summary

Generated 2026-11-10

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-02 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-10-14 | www.nasdaq.com | Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks | https://www.nasdaq.com/articles/heres-why-tyra-biosciences-tyra-poised-turnaround-after-losing-27-4-weeks
  • N2 | 2026-09-14 | www.nasdaq.com | Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains | https://www.nasdaq.com/articles/biotech-stocks-move-tyra-nasus-bionano-tenaya-make-gains
  • N3 | 2026-09-14 | www.nasdaq.com | Tyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3x3 | https://www.nasdaq.com/articles/tyra-prices-400-mln-underwritten-offering-stock-warrants-advance-dabogratinib-3x3
  • N4 | 2026-09-11 | www.nasdaq.com | Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials | https://www.nasdaq.com/articles/weekly-buzz-jnj-wins-fda-nod-axgn-hcwb-strike-deals-roiv-azn-gpcr-lead-clinical-trials
  • N5 | 2026-09-09 | www.nasdaq.com | Tyra Biosciences Reports Positive SURF302 Results; Plans Phase 3 In LG IR NMIBC | https://www.nasdaq.com/articles/tyra-biosciences-reports-positive-surf302-results-plans-phase-3-lg-ir-nmibc
  • N6 | 2026-09-04 | www.nasdaq.com | Noteworthy Friday Option Activity: TYRA, CLYM, AVBP | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-tyra-clym-avbp
  • N7 | 2026-05-20 | www.nasdaq.com | Wolfe Research Initiates Coverage of Tyra Biosciences (TYRA) with Peer Perform Recommendation | https://www.nasdaq.com/articles/wolfe-research-initiates-coverage-tyra-biosciences-tyra-peer-perform-recommendation
  • N8 | 2026-05-17 | www.nasdaq.com | Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares | https://www.nasdaq.com/articles/tyra-biosciences-stock-has-soared-280-year-one-fund-just-disclosed-buying-more-shares
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine